ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

3.51
0.22
( 6.69% )
Updated: 11:17:41

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.51
Bid
3.50
Ask
3.51
Volume
735,271
3.21 Day's Range 3.56
3.21 52 Week Range 37.98
Market Cap
Previous Close
3.29
Open
3.36
Last Trade
10
@
3.505
Last Trade Time
11:17:59
Financial Volume
$ 2,530,718
VWAP
3.4419
Average Volume (3m)
1,827,347
Shares Outstanding
88,214,054
Dividend Yield
-
PE Ratio
-0.95
Earnings Per Share (EPS)
-3.67
Revenue
234.04M
Net Profit
-323.99M

About Revance Therapeutics Inc

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Revance Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RVNC. The last closing price for Revance Therapeutics was $3.29. Over the last year, Revance Therapeutics shares have traded in a share price range of $ 3.21 to $ 37.98.

Revance Therapeutics currently has 88,214,054 shares outstanding. The market capitalization of Revance Therapeutics is $307.87 million. Revance Therapeutics has a price to earnings ratio (PE ratio) of -0.95.

RVNC Latest News

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four...

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.29-7.631578947373.83.873.2119620493.56248753CS
4-1.48-29.65931863734.994.993.2116625904.03403902CS
12-1.7-32.62955854135.217.563.2118273475.28654771CS
26-4.66-57.03794369658.179.7453.2117364516.23552424CS
52-28.16-88.916956109931.6737.983.21168753613.11949102CS
156-25.84-88.040885860329.3537.983.21121708818.41234164CS
260-9.9-73.825503355713.4137.983.2194937719.05019481CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.31
(80.74%)
53.47M
NIVFNewGenIvf Group Ltd
$ 2.1762
(67.40%)
45.26M
PEGYPineapple Energy Inc
$ 0.07615
(46.72%)
247.43M
FCUVFocus Universal Inc
$ 0.4151
(46.63%)
15.36M
INVZWInnoviz Technologies Ltd
$ 0.23
(33.26%)
7.79k
ISUNiSun Inc
$ 0.1566
(-95.45%)
7.32M
NWGLNature Wood Group Ltd
$ 7.66
(-54.54%)
379.52k
NUWENewellis Inc
$ 0.1637
(-43.36%)
13.56M
ICLKiClick Interactive Asia Group Ltd
$ 1.5001
(-40.71%)
479.41k
SGBXSafe and Green Holdings Corporation
$ 0.1551
(-29.18%)
5.02M
PEGYPineapple Energy Inc
$ 0.07615
(46.72%)
247.43M
SQQQProShares UltraPro Short QQQ
$ 11.445
(-4.63%)
70.92M
INTCIntel Corporation
$ 31.7625
(-9.53%)
56.15M
BDRXBiodexa Pharmaceuticals PLC
$ 1.31
(80.74%)
53.47M
NIVFNewGenIvf Group Ltd
$ 2.1762
(67.40%)
45.26M

RVNC Discussion

View Posts
randychub randychub 37 minutes ago
Another 1500 shares for me.
👍️0
alertmeipp alertmeipp 1 hour ago
Would be extreme bullish if RVNC re-affirm their at least 280mm sales guidance given Botox's weakness.

We can all hope. I bet Abbv would love to buyout RVNC even for 4-5 billions as then they will have a better product to push. But obviously, they can't due to competition concern.
👍️0
DewDiligence DewDiligence 2 hours ago
1Q24 Botox sales by indications and geography: #msg-174309306.
👍️ 2
Emannow Emannow 3 hours ago
AbbVie just released Q1 2024 numbers and US Botox was down 4.9% YOY and Juvederm was down 13.9% YOY! And that is with the Botox price increase!!! Take out the price increase and Botox is down 7 to 8%!

Allergan is losing market share in aesthetics! Now we know why so many directors and VPs are leaving Allergan! I would expect to start seeing layoffs and open jobs go unfulfilled! This loss of market share will continue as both Botox and Juvederm are 20 yr old products and patients are migrating to new better products!

Any practice still using only Botox and Juvederm is on a sinking ship! Allergan will continue to raise prices to make up for lost market share and squeeze profits from injectors.
👍️ 4
alertmeipp alertmeipp 3 hours ago
Are you not concerning that your business will be taken away sooner or later by your competitors that offer the new and better product?

Seems rather naive on your part to not trying harder on this as it seems you agreee Daxxify is the best and cost less?
👍️ 1
biotech_researcher biotech_researcher 3 hours ago
Soma, thank you for taking the time post your informative information.
👍️ 1
mrwilson31 mrwilson31 4 hours ago
So owning a few spas verses reading information on IHUB should give them enough information that Daxxify is what they should be offering?

Read that again. You are stating that he/she should run their business based on the information from a message board? 🤦‍♂️🤦‍♂️🤦‍♂️🤦‍♂️🤦‍♂️

How is your Med/Spa or clinic going with toxins?
💩 1 🤡 1
edcoolidge edcoolidge 11 hours ago
Honestly your story has always been suspect. You have the information provided here to know that Daxxify is the best toxin when injected properly and can make a practice more money so you should be enthusiastically offering it. You only showed up on this board after Daxxify was approved and have shown at times a complete lack of understanding about toxin injection. You claim to own practices but there's no way to verify that. I can't prove it's false either but frankly I think you're not truthful and have ulterior motives.
💯 3 🤡 2
boraborak38 boraborak38 12 hours ago
Always good posts and info soma. In my circles (and I own practices), I am not seeing adoption of Daxxify. I asked another well known owner in my area what she is seeing and she said:
“ The daxxify buzz kind of died. I haven’t heard or seen anything on the groups good or bad. Revance has “restructured” and let go of some positions recently.”
So….i think it depends who you ask. It’s no secret that their sales force has been upended. And the relationships that take time to build have stalled. I saw something similar a few years ago with the lawsuit against Evolus. Sales staff got turned upside down when they were essentially frozen from doing business. And so it took a long time to rebuild that.
I don’t hear people/patients asking for Daxxify yet either. You can call me some shill for another toxin company but this is the truth. And the things I have said the past couple years have been pretty accurate.
I’m still long some shares around $5.50 FWIW
👍️ 1
edcoolidge edcoolidge 13 hours ago
That explains why Galderma shill and perpetual loser CosmeticMD was working overtime today to tag my posts with clown emojis. The majority of patients who try Daxxify with a skilled injector stick with it. That's bad news for those desperate to maintain the status quo.
👍️ 4 🤡 1
soma2022 soma2022 16 hours ago
The strategy of lowering the price and changing the messaging to acts fast and lasts and the $75 rebate to get injectors and patients motivated to try it appears to be working. What strategic change on price, messaging, rebates, etc would you make? This is not a marketing issue. This is a getting word of mouth out issue and my 800 patients are acting like Daxxify ambassadors in my geography. Do you feel that the product is not gaining traction in well established accounts?
👍️ 5
alertmeipp alertmeipp 16 hours ago
>> Foley is making a good decision!!

Finally. :) All while stock keeps making all time low almost daily.
👍️0
alertmeipp alertmeipp 16 hours ago
Ms.Dtox - If you don't mind, where about are u in the org chart? Are you still with the company?

You seems to hate the company or at least its strategy. You have already lost a ton on the stock. Have you tried to raise your concern to management?
👍️ 2
Emannow Emannow 17 hours ago
Had a discussion today with a friend who has connections with RVNC, Evolus and Galderma. RVNC had so many Daxi promotions in Q1 that the reps from the other companies were complaining about the average price of a vial of Daxi at $240 to $250. The RVNC reps were moving Daxi into new accounts and the competition was upset with the low price!

In retrospect, this is EXACTLY what needs to happen which will motivate new injectors to put Daxi into new faces. The aesthetic patient is looking for the best spend for their dollar and Daxi will give this patient double duration, quick onset and improved skin tone as compared to their normal toxin! RVNC needs to continue these Daxi price promotions for.a few quarters and grow the base of Daxi users! For once, Foley is making a good decision!!
👍️ 6 😀 1
Ms.Dtox Ms.Dtox 17 hours ago
(I don’t see an edit button) I meant to say, there is no effective strategy in place.
👍️0
Ms.Dtox Ms.Dtox 17 hours ago
Hi think the price change and messaging HAD TO HAPPEN and believe course corrections do not happen quickly when there is an effective strategy in place for Daxxify commercial launch other than what’s already been mentioned.
👍️0
alertmeipp alertmeipp 19 hours ago
The current price is so low, any buyout will need sky high premiums. I think many will be upset with a buyout price of 10 bucks

But $10 is 300 premium
👍️ 3
edcoolidge edcoolidge 19 hours ago
Great post soma! In the hands of "authoritative and expert injectors" Daxxify is clearly the best toxin on the market. This of course dovetails with what I've seen on social media and heard from my own contacts. Unskilled/unscrupulous CosmeticMDs/PAs/nurses who "couldn't quite figure it out" or "didn't want to take the time and effort to" figure it out lest they lose their kickbacks have been less enthusiastic about Daxxify. I am not a practice owner myself.
👍️ 1 🤡 1
Tomdontworry Tomdontworry 19 hours ago
This does not apply to Pharma. Each of the mega pharma companies put aside billions per year (per company) for strategic acquisitions (companies in p2, p3, post approval early stages). It is a cut throat competition to stay ahead of the pack, or become the next PFE, BMY. Now, RVNC is opex heavy, but find 100m in synergies (legal, hr, finance, c suite, hq, etc) and you got yourself a break-even earner purchase and potential future pipeline…
👍️ 4
alertmeipp alertmeipp 20 hours ago
Yes higher rate will reduce demand for speculative stocks. But I just don’t think it’s a significant factor
👍️0
alertmeipp alertmeipp 20 hours ago
Yes and no insider buy (maybe in blackout) and no activists interested as well


I still hope to see some 13G or F soon at current valuation
👍️ 3
Tomdontworry Tomdontworry 20 hours ago
Daxi is best in class and costs similar, if not cheaper, than botox. There is huge growth potential in Aesthetics and Therapeutics markets, and dont forget the RHA fillers AND the new lip flip (no more fish lips??) campaign. My guess wall st lost faith in Mark’s failures, on top of non-existing IR dept. Now what i dont understand is why big pharma (Pfizer failed to acquire Allergan) has not yet bough this co for 2-3B.. every pharma co has huge budgets each year for acquisitions, and with the right leadership this company can be profitable sooner than projections with blockbuster potential… what am i missing?
👍️ 6
edcoolidge edcoolidge 20 hours ago
These big ticket items are much more sensitive to financing rate and inflation.
Guess what, automakers have actually done well despite higher rates and record prices. TSLA is a meme stock so we can leave that out of discussion. There has been a slowdown in growth of EV adoption which is unique to that sector sure but the other EV companies you mentioned are also unprofitable so are suffering the same fate as RIVN and RVNC. Interest rates are impacting the desire to own speculative stocks more than they're impacting the underlying business. This is my last post on this as it's obviously tangential.

🤡 1
girlfriend girlfriend 20 hours ago
It's screwed up because you can't really factor in the shorts. The shorts feed off small bios and small caps when the markets are down or there is no news no updates no positives....the company could put out some kind of PR to calm every body down if the treatment(s) look like they will produce revenues and take market share. Just my take but the shorts can destroy a stock price.
👍️ 4
alertmeipp alertmeipp 20 hours ago
It’s down because EV was hyped up and now people realize EV is not for everyone. R1s and R1j are not cheap, they cost about 70k usd after the recent car. These big ticket items are much more sensitive to financing rate and inflation.

Even Tesla is down 30 ytd

Nio xpev fisker lucid all down even more. So for rivn , its a sector thing

For RVNC, Eols is doing well, Botox sales was growing fine. So it’s not even a sector thing
👍️ 2
alertmeipp alertmeipp 20 hours ago
Yes those who subscribed to the recent secondary already down like 50 percent

Doesn’t look good for Barlays at all

It’s odd. The purpose of the raise was to clear overhang. The stock drops half after the overhang is removed

Like how screw up is that
👍️ 2
edcoolidge edcoolidge 21 hours ago
Why is RIVN down? Because their expenses have grown faster than their revenue. Because they're a newcomer in an industry with established brand heavyweights. Because the market is unsure if they can become profitable before they go bankrupt in a fearful interest rate environment. But if you've been following the story closely you know that their products are excellent—some of the best available—in a business with an increasing TAM. It sounds a lot like another stock we talk about frequently here, which might be why their YTD charts are nearly identical.
🤡 1
alertmeipp alertmeipp 21 hours ago
I know what u are saying actually but I just disagree that it’s a general market thing. The drop is very specific to RVNC, same for RIVN
👍️ 1
vinmantoo vinmantoo 21 hours ago
As you all know, I am a long time injector of Daxxify since Prevu Dec 2022. I launched conservatively to a small portion of my practice, and since that time, Daxxify has taken over 80% of my own NT business (not including my nurse injectors). I used to be Botox only. This is the biggest revenue shift that I have seen in my practice in 20 years.

I am also seeing gradual adoption of Daxxify from many of my nurse injectors the past 3 quarters and we did over 6 figures of Daxxify purchases (over 400 vials) in Q1 2024. The march $75 rebates did help to get us to buy more Daxxify and to entice clients to try Daxxify. This represents over 500% growth over the Daxxify vials I used in Q12023. Although I am still the largest single injector of Daxxify in my organization, my nurse injectors, as a group, exceeded my total vials injected in Q4 2023 and have continued to grow their percentage of Daxxify used within my company.

Soma, thanks so much for your input. It is very encouraging to RVNC investors as they watch the stock price continue to sink. You should message Ms.Dtox before she sinks further into depression over RVNC as her big losses and tell her not to lose hope as it may yet turn into a gain.
👍️ 2
edcoolidge edcoolidge 21 hours ago
I never said RVNC is down because of interest rates and inflation. Revance is down because they're a loss making company and they've grown expenses faster than revenues. The market has turned extremely negative on companies like that and punished them unduly on days where rates have moved higher. RVNC is essentially priced for bankruptcy at this point, as is RIVN, and many other companies, some of whom will go bankrupt, and many of whom will not and the market will have been wrong about.
👍️ 4 🤡 2
alertmeipp alertmeipp 21 hours ago
Thanks soma2022 for such a valuable posts
👍️ 1
alertmeipp alertmeipp 21 hours ago
If you still think rvnc is down 60 percent ytd mainly because of inflation and interest rate, I think we have to agree to disagree.

RVNC is not even in an highly inflation or rate sensitive sector
👍️ 1
Monksdream Monksdream 21 hours ago
RVNC new 52 week low
👍️0
alertmeipp alertmeipp 21 hours ago
As you said, RIVN is in a much more capital intensive market. Plus they have to scale up much bigger in order to compete on cost. Currently, their gross profit is still negative. So very different story
👍️0
Emannow Emannow 22 hours ago
One of the offices I am friends with uses approximately 350 vials of Daxi a quarter. This practice was not part of the Daxi Prev program. The doctor does 95% of the toxin injections and there are 3 PA who injected the other 5%. The PAs have not converted patients to Daxi and are still using Botox. The doctor has converted 98% of the patients to Daxi and now has more availability on the schedule since the toxin patients are get more duration. The doctor is also making more profit per day/month using Daxi. Also, this office is now 100% RHA and no longer uses Juvederm.

It took the doctor about 3 months to master the Daxi injection technique. 98% of the patients stay with Daxi and do not go back to Botox.

On another topic, rumor is that both Daxi and RHA achieved their sales numbers in Q1.
👍️ 7 💯 1
marthambles marthambles 22 hours ago
I bought more earlier, but with a very tight stop loss.
👍️ 2
edcoolidge edcoolidge 22 hours ago
Don't be ridiculous. I already posted about one, except they have billions in cash.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174304081
🤡 1
soma2022 soma2022 22 hours ago
Call For Doctors/Med Spa owners on this Board to Share Daxxify Sales Data

As you all know, I am a long time injector of Daxxify since Prevu Dec 2022. I launched conservatively to a small portion of my practice, and since that time, Daxxify has taken over 80% of my own NT business (not including my nurse injectors). I used to be Botox only. This is the biggest revenue shift that I have seen in my practice in 20 years.

I am also seeing gradual adoption of Daxxify from many of my nurse injectors the past 3 quarters and we did over 6 figures of Daxxify purchases (over 400 vials) in Q1 2024. The march $75 rebates did help to get us to buy more Daxxify and to entice clients to try Daxxify. This represents over 500% growth over the Daxxify vials I used in Q12023. Although I am still the largest single injector of Daxxify in my organization, my nurse injectors, as a group, exceeded my total vials injected in Q4 2023 and have continued to grow their percentage of Daxxify used within my company.

I am seeing a 54% Daxxify adoption rate within my practice (7 of 13 nurses who trialed it in Q2/Q3 2023 are now ramping up sales in a meaningful way = 10 or more vials a month of Daxxify purchases). 25% are ramping up at a slower rate and 25% tried it and kind of gave up and couldn't quite figure it out or didn't want to take the time and effort to. This implies that roughly 50% of experienced nurse injectors will take 6 to 9 months to get comfortable with their injection outcomes and sales pitch before blowing it out, these nurse injectors tend to be our more authoritative and expert injectors - the type of nurse injectors that clients trust implicitly with 10 or more years of experience. These nurses are the heavy lifters in the NT industry that typically do 40 to 70 vials of NT each month. They likely account for 50% of the US NT market. They are my heavy hitters and largest profit centers. Moreover, the transition to Daxxify is making our organization more profitable with higher client satisfaction rates.

Emmanow, Edcoolidge, Boraborak38, others: would you be able to share some of your Daxxify purchase data for the board to gain some color on traction of Daxxify within your practice?
👍️ 12 💯 3
alertmeipp alertmeipp 22 hours ago
RVNC is much worse than most recently. Actually, find me another name that has 350mm cash on hand, that is down close to 40 percent MTD.

It’s clearly not just inflation or interest rate.
👍️0
soma2022 soma2022 23 hours ago
Perhaps the better question to Ms. Dtox would be: Do you feel the pricing change last fall and the change in messaging early this year and injectors getting more experience with the product have helped to course correct Daxi and do you feel that the worse is behind the Daxxify commercial launch?
👍️ 4
alertmeipp alertmeipp 23 hours ago
Anyone selling? Buying?
👍️0
Emannow Emannow 23 hours ago
The Board of Directors meeting is May 1st so there will probably be a preliminary earnings announcement before their May 5th Q1 date.

Also AbbVie will announce Botox sales tomorrow morning!

RVNC has cash to get them through the end of 2025.

CD Daxi sales will start May 9th…there is already a backlog of orders!

China approve any day!

I am convinced AbbVie has a fund which is shorting RVNC.
👍️ 8
edcoolidge edcoolidge 23 hours ago
There are dozens or hundreds of comparisons just like this. RIVN makes fine products but they're unprofitable and their pathway to profitability is uncertain—not something people want to own in this interest rate environment. I don't own that stock but I've been looking for an entry point as I expect them to survive and they could easily be worth 10x in 10 years—but Rivian is far more likely than Revance to go bankrupt given the capital intensive nature of their business.

🤡 1
Tomdontworry Tomdontworry 23 hours ago
Trading for cash in bank now. Best product on market but terrible execution. No IR department to pitch the business. Crazy how they offered at 6.25 and a month later price is 3.25. They need to support the stock and Foley is silent until Q1 call which is when? Hope we get a PR…
👍️ 3
edcoolidge edcoolidge 23 hours ago
You seem to be very naive and unaware about the movement of interest rates and inflation or that the exact same thing happening to RVNC is happening to many other loss-making companies right now. Some of these companies will go bankrupt but many won't. Market irrationality always lasts longer than you think but it doesn't last forever.
🤡 1
alertmeipp alertmeipp 24 hours ago
For sure, I would have never thought this will drop to this low.

Unless some fraud going on, I see this stock worth double digits at least.
👍️ 1 🤡 1
alertmeipp alertmeipp 24 hours ago
They just raised 100mm

And they have 250mm cash on hand end of last year

They have CD and potential oversea milestones coming

But the sentiment is worse than awful

I think it’s buying time and have acted accordingly
👍️ 2
biotech_researcher biotech_researcher 24 hours ago
The number of posters here buying this as it was falling day after day over the last year is startling.
👍️ 4 🤡 1
mrwilson31 mrwilson31 24 hours ago
I thought the 3.50-3.70 range was going to be bottom.

May look like 2.25-40 range now.

Looking for a point to jump in.
👍️ 2
biotech_researcher biotech_researcher 24 hours ago
This feels different.
🤡 1

Your Recent History

Delayed Upgrade Clock